Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • 4SC-205: Phase I final data

    4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Product: 4SC-205 Business: Cancer Molecular target: Kinesin spindle protein (KSP) (Eg5) (TRIP5) Description: Oral inhibitor of kinesin spindle protein (KSP; Eg5; TRIP5) …

    Published on 6/29/2015
  • AlloMap Molecular Expression Test: Postmarketing study data

    CareDx Inc. (NASDAQ:CDNA), Brisbane, Calif. Product: AlloMap Molecular Expression Test Business: Diagnostic Molecular target: NA Description: Non-invasive multi-gene expression profiling blood diagnostic Indication: …

    Published on 6/29/2015
  • Andexanet alfa: Additional Phase III data

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Product: Andexanet alfa (PRT4445, PRT064445) Business: Hematology Molecular target: NA Description: Recombinant protein that reverses the …

    Published on 6/29/2015
  • ARGX-110: Preliminary Phase I data

    arGEN-X N.V. (Euronext:ARGX), Breda, the Netherlands Product: ARGX-110 Business: Cancer Molecular target: CD70 (CD27L) Description: Human mAb against CD70 (CD27L) Indication: Treat cancer Endpoint: Safety and dose-…

    Published on 6/29/2015
  • ASP2215: Additional Phase I/II data

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: ASP2215 Business: Cancer Molecular target: FMS-like tyrosine kinase 3 (FLT3) (CD135); AXL receptor tyrosine kinase (AXL) (UFO) Description: Small molecule AXL …

    Published on 6/29/2015
  • Betalutin: Preliminary Phase I/II data

    Nordic Nanovector ASA (OSE:NANO), Oslo, Norway Product: Betalutin Business: Cancer Molecular target: CD37 Description: Lutetium-177 radiopharmaceutical conjugated to an anti-CD37 mAb Indication: Treat relapsed non-…

    Published on 6/29/2015
  • CPX-351: Phase III data

    Celator Pharmaceuticals Inc. (NASDAQ:CPXX), Ewing, N.J. Product: CPX-351 Business: Cancer Molecular target: DNA polymerase; Topoisomerase II (TOP2) Description: Liposomal formulation of cytarabine and daunorubicin …

    Published on 6/29/2015
  • Cyramza ramucirumab: Additional Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Cyramza ramucirumab (LY3009806, IMC-1121B) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1) …

    Published on 6/29/2015
  • DCR-MYC: Additional Phase I data

    Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA), Watertown, Mass. Product: DCR-MYC Business: Cancer Molecular target: v-myc myelocytomatosis viral oncogene homolog (MYC) (c-Myc) Description: Dicer substrate short interfering…

    Published on 6/29/2015
  • DCVax-Direct: Additional Phase I/II data

    Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Product: DCVax-Direct Business: Cancer Molecular target: Not applicable Description: Autologous dendritic cells designed to uptake tumor antigens in vivo …

    Published on 6/29/2015
  • Eloctate RFVIIIFc: Interim Phase III data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden UCB Group (Euronext:UCB), Brussels, Belgium Product: Eloctate RFVIIIFc (Elocta) Business: Hematology Molecular target…

    Published on 6/29/2015
  • Factor IX-albumin fusion protein: Phase III data

    CSL Ltd. (ASX:CSL), Melbourne, Australia Product: Factor IX-albumin fusion protein, rIX-FP (CSL654) Business: Hematology Molecular target: Factor IX Description: Recombinant fusion protein linking recombinant …

    Published on 6/29/2015
  • Factor IX-albumin fusion protein: Phase II/III data

    CSL Ltd. (ASX:CSL), Melbourne, Australia Product: Factor IX-albumin fusion protein, rIX-FP (CSL654) Business: Hematology Molecular target: Factor IX Description: Recombinant fusion protein linking recombinant …

    Published on 6/29/2015
  • G305: Phase I data

    Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Product: G305, ID-G305 Business: Cancer Molecular target: Cancer/testis antigen 1B (CTAG1B) (NY-ESO-1) Description: Immunotherapy consisting of recombinant cancer/testis…

    Published on 6/29/2015
  • GLA-SE: Phase I data

    Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Product: GLA-SE (G100) (formerly GL-100, ID-G100) Business: Cancer Molecular target: Toll-like receptor 4 (TLR4) Description: Toll-like receptor 4 (TLR4) agonist …

    Published on 6/29/2015
  • Herpes simplex virus type 2: Phase I/II data

    Vical Inc. (NASDAQ:VICL), San Diego, Calif. Product: Herpes simplex virus type 2 (HSV-2) vaccine (Vaxfectin-formulated plasmid DNA HSV-2 vaccine) Business: Infectious Molecular target: Not applicable Description: DNA …

    Published on 6/29/2015
  • Idarucizumab: Interim Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Idarucizumab (dabigatran antidote) (BI 655075) Business: Hematology Molecular target: NA Description: Fab fragment against dabigatran Indication: Reverse …

    Published on 6/29/2015
  • Imalumab: Phase I data

    Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: Imalumab (BAX069, Bax69) Business: Cancer Molecular target: Macrophage migration inhibitory factor (MIF) Description: Recombinant mAb targeting oxidized …

    Published on 6/29/2015
  • Intranasal fluticasone propionate: Phase III data

    OptiNose Inc., Yardley, Pa. Product: Intranasal fluticasone propionate (OPN-375) Business: Inflammation Molecular target: Glucocorticoid receptor (GCCR) Description: Intranasal fluticasone delivered using the OptiNose …

    Published on 6/29/2015
  • KTN3379: Interim Phase I data

    Kolltan Pharmaceuticals Inc., New Haven, Conn. Product: KTN3379 Business: Cancer Molecular target: Epidermal growth factor receptor 3 (EGFR3) (HER3) (ErbB3) Description: Human mAb against epidermal growth factor …

    Published on 6/29/2015
  • LV305: Phase I data

    Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Product: LV305, ID-LV305 Business: Cancer Molecular target: NA Description: Lentiviral vector engineered to deliver antigen-encoding nucleic acids directly to dendritic …

    Published on 6/29/2015
  • Lyxumia lixisenatide: Additional Phase IIIb data

    Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Lyxumia lixisenatide (AVE0010, ZP10) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 …

    Published on 6/29/2015
  • Masitinib: Phase Ib/II data

    AB Science S.A. (Euronext:AB), Paris, France Product: Masitinib (Masican) (AB1010) Business: Cancer Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell factor (…

    Published on 6/29/2015
  • MEDI4736: Additional Phase Ib data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: MEDI4736 Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: …

    Published on 6/29/2015
  • Metadoxine ER: Phase II data

    Alcobra Ltd. (NASDAQ:ADHD), Tel Aviv, Israel Product: Metadoxine ER (MDX) (MG01CI) Business: Neurology Molecular target: Serotonin (5-HT2B) receptor Description: Extended-release formulation of metadoxine, a selective …

    Published on 6/29/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993